![Author's Photo](https://d1b6lhn2ymmy1x.cloudfront.net/journalist-headshots/gibney-michael-square-600x600.jpg)
Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
185 articles by Michael Gibney
-
Gilead eyes ‘ending the HIV epidemic’ via incremental progress
July 18, 2024 -
Has pharma emerged from the ‘age of uncertainty’?
July 16, 2024 -
As feds crack down on PBMs for drug costs, Big Pharma could lose some of the heat
July 11, 2024 -
FDA approval is just the beginning. Now Lilly’s Kisunla faces the tough Alzheimer’s market.
July 9, 2024 -
How BeiGene is taking on established blockbusters with an expanding blood cancer arsenal
July 2, 2024 -
Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections
June 27, 2024 -
Can Moderna’s COVID-flu combo shot improve flagging vaccination rates?
June 25, 2024 -
Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’
June 18, 2024 -
Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now
June 13, 2024 -
As Big Pharma places bigger bets on ADCs, here’s where the field is headed next
June 11, 2024 -
A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers
June 6, 2024 -
Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old
June 3, 2024 -
As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’
May 30, 2024 -
Can robots break the cell therapy bottleneck?
May 29, 2024 -
AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets
May 23, 2024 -
Drug shortages, cost concerns and iffy access — how DTC and telehealth could even the playing field
May 22, 2024 -
Big Pharma leaders juggle pricing and access as IRA and supply constraints loom large
May 16, 2024 -
Big Pharma’s most improved drugs: a new generation of blockbusters
May 14, 2024 -
Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown
May 9, 2024 -
AZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
May 8, 2024 -
$4M+ gene therapies? How payers can adapt to a new reality of pricey ‘cures’
May 2, 2024 -
Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters
April 30, 2024 -
As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply
April 25, 2024 -
How pharma’s surging M&A is impacting the industry’s tech sector
April 11, 2024 -
Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future
April 9, 2024